Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2019

24.10.2019 | Research Article

Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment

verfasst von: María Ángeles Campos Fernández de Sevilla, Marta Gallego Úbeda, Maria Tovar Pozo, Emilio García-Cabrera, Beatriz Monje García, Federico Tutau Gómez, Laura Delgado Téllez de Cepeda, Irene Iglesias-Peinado

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background Adherence to direct-acting antivirals could be a predictor response to these treatments in hepatitis C. Objective To assess the ability of three methods of measuring adherence to direct-acting antivirals [pill counts, pharmacy dispensing record and Simplified Medication Adherence Questionnaire (SMAQ)] as predictors of their effectiveness. Setting Study conducted by the pharmacy department of the hospital. Methods: A retrospective study was performed. Patients ≥ 18 years with hepatitis C that started and completed treatment with direct-acting antivirals between the 1st-April-2015 and 28st-February-2016 were enrolled. To evaluate the predictive ability to obtain a response to treatment, Chi squared test, Mann–Whitney-U test and ROC-curves were used. Main outcome measure Adherence to antivirals was assessed by three methods and response to treatment, which was defined as obtaining a viral load of hepatitis C virus ≤ 15UI/ml at week 12 after the end of treatment. Results 128 patients were enrolled. The overall average adherence obtained with SMAQ (99.09%) was similar to the pill counts (96.40%, p = 0.043) and pharmacy dispensing record (91.10%, p = 0.02). There was no correlation between the percentage of patients considered as adherent by SMAQ (99.09%) and the achievement of response to treatment (96.40%, p = 0.999). The ROC-curve obtained for the pill count method shows a global area under the curve of 0.53. For pharmacy dispensing record method, patients with an adherence ≤ 66.66% have a high probability of not achieving response (sensitivity and specificity of 79.00% and 100.00%, respectively). Conclusions Pharmacy dispensing record is shown as the best indicator of adherence to predict therapeutic failure in our study.
Literatur
1.
Zurück zum Zitat Terrault N, Monto A, Stinchon MR, Rusie E, Moreo K. New therapies, evidence, and guidance in hepatitis C management: expert practices and insights from an educational symposium at the AMCP 27th annual meeting expo. J Manag Care Spec Pharm. 2015;21(9):S1–14.PubMed Terrault N, Monto A, Stinchon MR, Rusie E, Moreo K. New therapies, evidence, and guidance in hepatitis C management: expert practices and insights from an educational symposium at the AMCP 27th annual meeting expo. J Manag Care Spec Pharm. 2015;21(9):S1–14.PubMed
2.
Zurück zum Zitat Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm. 2015;37(5):698–708.CrossRef Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm. 2015;37(5):698–708.CrossRef
3.
Zurück zum Zitat Puenpatom A, Hull M, McPheeters J, Schwebke K. Treatment discontinuation, adherence, and real-world effectiveness among patients treated with ledipasvir/sofosbuvir in the United States. Infect Dis Ther. 2017;6(3):423–33.CrossRef Puenpatom A, Hull M, McPheeters J, Schwebke K. Treatment discontinuation, adherence, and real-world effectiveness among patients treated with ledipasvir/sofosbuvir in the United States. Infect Dis Ther. 2017;6(3):423–33.CrossRef
4.
Zurück zum Zitat Benítez García B, González del Valle L, Capilla Santamaría E, Perez Robles T, Herrero Ambrosio A. CPC-062 hepatitis C and adherence. Eur J Hosp Pharm. 2013;20((Suppl 1)):A187–8. Benítez García B, González del Valle L, Capilla Santamaría E, Perez Robles T, Herrero Ambrosio A. CPC-062 hepatitis C and adherence. Eur J Hosp Pharm. 2013;20((Suppl 1)):A187–8.
5.
Zurück zum Zitat The American Association for the Study of Liver Diseases and the Infectious Disease Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org Introduction. From wwwHCVGuidance.org Sept. 2017; vol. 21. The American Association for the Study of Liver Diseases and the Infectious Disease Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. www.​hcvguidelines.​org Introduction. From wwwHCVGuidance.org Sept. 2017; vol. 21.
6.
Zurück zum Zitat Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int. 2016;10(2):310–9.CrossRef Petersen T, Townsend K, Gordon LA, Sidharthan S, Silk R, Nelson A, et al. High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatol Int. 2016;10(2):310–9.CrossRef
7.
Zurück zum Zitat Walker DR, Juday TR, Manthena SR, Jing Y, Sood V. The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir. Clin Outcomes Res. 2015;7:637–42. Walker DR, Juday TR, Manthena SR, Jing Y, Sood V. The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir. Clin Outcomes Res. 2015;7:637–42.
8.
Zurück zum Zitat Burton MJ, Voluse AC, Patel AB, Konkle-Parker D. Measuring adherence to hepatitis C direct-acting antiviral medications: using the VAS in an HCV treatment clinic. South Med J. 2018;111(1):45–50.CrossRef Burton MJ, Voluse AC, Patel AB, Konkle-Parker D. Measuring adherence to hepatitis C direct-acting antiviral medications: using the VAS in an HCV treatment clinic. South Med J. 2018;111(1):45–50.CrossRef
9.
Zurück zum Zitat Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplied medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. Aids. 2002;16(4):605–13.CrossRef Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplied medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. Aids. 2002;16(4):605–13.CrossRef
10.
Zurück zum Zitat Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRef Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRef
11.
Zurück zum Zitat European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61(2):373–95.CrossRef European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61(2):373–95.CrossRef
12.
Zurück zum Zitat De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1):30–5.CrossRef De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1):30–5.CrossRef
13.
Zurück zum Zitat Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–16.CrossRef Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105–16.CrossRef
14.
Zurück zum Zitat Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir. Dig Dis Sci. 2015;60(4):1045–51.CrossRef Vo KP, Vutien P, Akiyama MJ, Vu VD, Ha NB, Piotrowski JI, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir. Dig Dis Sci. 2015;60(4):1045–51.CrossRef
15.
Zurück zum Zitat Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine. 2016;95(28):e4151.CrossRef Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine. 2016;95(28):e4151.CrossRef
16.
Zurück zum Zitat Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, et al. Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study). Enferm Infecc Microbiol Clin. 2008;26(3):127–34.CrossRef Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, et al. Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study). Enferm Infecc Microbiol Clin. 2008;26(3):127–34.CrossRef
17.
Zurück zum Zitat Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez C-G, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, et al. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. Expert Opin Drug Saf. 2018;11:1–7. Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez C-G, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, et al. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. Expert Opin Drug Saf. 2018;11:1–7.
18.
Zurück zum Zitat Ji F, Wei B, Yeo YH, Ogawa E, Zou B, Stave CD, et al. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther. 2018;47(5):550–62.CrossRef Ji F, Wei B, Yeo YH, Ogawa E, Zou B, Stave CD, et al. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther. 2018;47(5):550–62.CrossRef
19.
Zurück zum Zitat Nogués Solán X, Sorli Redó ML, Villar García J. Tools to measure treatment adherence. Ann Med Int. 2007;24(3):138–41. Nogués Solán X, Sorli Redó ML, Villar García J. Tools to measure treatment adherence. Ann Med Int. 2007;24(3):138–41.
20.
Zurück zum Zitat Mathes T, Antoine S-L, Pieper D. Factors influencing adherence in hepatitis-C infected patients: a systematic review. BMC Infect Dis. 2014;14:203.CrossRef Mathes T, Antoine S-L, Pieper D. Factors influencing adherence in hepatitis-C infected patients: a systematic review. BMC Infect Dis. 2014;14:203.CrossRef
Metadaten
Titel
Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment
verfasst von
María Ángeles Campos Fernández de Sevilla
Marta Gallego Úbeda
Maria Tovar Pozo
Emilio García-Cabrera
Beatriz Monje García
Federico Tutau Gómez
Laura Delgado Téllez de Cepeda
Irene Iglesias-Peinado
Publikationsdatum
24.10.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2019
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00917-0

Weitere Artikel der Ausgabe 6/2019

International Journal of Clinical Pharmacy 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.